Baucus hires Finance Committee health counsel
David Schwartz joins the Senate Finance Committee's Health and Welfare team as health counsel March 13 after serving three years as a fellow and then as a detailee from the Social Security Administration. His work on the committee will focus on issues related to pharmacies, drug pricing and benefits, health information technology, medical malpractice and the integrity of federal healthcare programs. Schwartz also will conduct investigations related to the operation of the Medicare and Medicaid programs...
You may also be interested in...
The fourth quarter proved to be challenging for Novartis, with its dermatology, ophthalmology and oncology products – and Zolgensma – feeling the impact of COVID-19 lockdowns. The company is hoping for much better things in the second part of 2021.
Together, we will improve patient health and experiences while lowering costs across the continuum of care.” This quote, from Andrew Witty, CEO of US health services management company Optum, after the company sealed its acquisition of DaVita Medical Group in 2019, encapsulates the oft-declared goals of vertical integration: efficiencies, improved quality of care, reduced costs. But is this the reality?
Canada’s Valeo Pharma says it intends to pursue discussions for the inclusion of its Redesca enoxaparin biosimilar on all other provincial formularies, after being backed for listing on the Quebec public health plan.